Compare Boston Scientific Corporation (BSX) vs Conagra Brands Inc (CAG) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

Conagra Brands (CAG) trades at $15.11, up 1.75% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $11.6B revenue and $1.15B net income, but faces challenges with negative margins projected for 2026. Recent developments include a 50% dividend cut to $0.18 and new leadership appointments under CEO John Brase, who recently purchased 35,000 shares.

The outlook remains cautious despite attractive valuation metrics (P/E 10.06, P/S 0.64). While analyst consensus leans Hold (62.5%), the stock trades above the $13.67 target. Key risks include persistent inflation pressure, declining sales, and margin compression. The dividend reduction provides financial flexibility but signals ongoing turnaround challenges.